Armata Pharmaceuticals Secures $5.25 Million DoD Grant to Advance Groundbreaking Phage Therapy for Staphylococcus aureus Bacteremia
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a leader in the development of cutting-edge bacteriophage therapies, has been awarded an additional $5.25 million in non-dilutive funding by the U.S. Department of Defense (DoD). This significant grant, facilitated through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) and the Joint…
